Stoke Therapeutics, Inc.
STOK
$32.49
-$0.15-0.46%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/11/2026
-
SeekingAlpha
5/11/2026
-
The Cerbat Gem
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
5/11/2026
-
Simply Wall St
5/11/2026
-
MarketBeat
5/11/2026
-
TipRanks Financial Blog
5/9/2026
-
The Cerbat Gem
5/9/2026
-
Simply Wall St
5/9/2026
-
MarketBeat
5/8/2026
-
MarketBeat
5/8/2026
-
TipRanks Financial Blog
5/8/2026
-
SeekingAlpha
5/8/2026
-
Seeking Alpha: Transcripts
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Business Wire
5/6/2026
-
Zacks Investment Research
5/6/2026
-
Zacks Investment Research
5/5/2026
-
Zacks Investment Research
5/3/2026
-
MarketBeat
5/2/2026
-
Simply Wall St
5/1/2026
-
SeekingAlpha
5/1/2026
-
Seeking Alpha - Long Ideas
5/1/2026
-
Seeking Alpha - Healthcare
4/30/2026
-
Business Wire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 7, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
781 430 8200
Address
45 Wiggins Avenue
Bedford, MA 01730
Bedford, MA 01730
Country
Year Founded
Business Description
Sector
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of...
more